Heterobifunctional Targeted Protein Degraders one-day meeting

The upcoming one-day DMDG scientific meeting will focus on the topic of Targeted Protein Degraders (TPDs), specifically the heterobifunctional class. These substances challenge the conventional physicochemical parameters necessary for oral drug delivery, making their optimization through DMPK (Drug Metabolism and Pharmacokinetics) a complex task. Despite these challenges, the catalytic mode of action of TPDs indicates that smaller drug amounts could be sufficient for effective treatment. Recent clinical candidate disclosures demonstrate that achieving adequate exposure can lead to pharmacological effects surpassing traditional target inhibition.

The meeting is organized by Caroline Rynn from Roche, UK & DMDG, and Heide Duevel from Merck KGaA, Darmstadt, Germany. It aims to gather renowned experts to discuss the application of DMPK optimization strategies and quantitative translational PKPD (Pharmacokinetics/Pharmacodynamics) frameworks for predicting human PK and the efficacious dose of heterobifunctional TPDs.

This event is particularly relevant for professionals currently working with TPDs in academia, pharmaceuticals, biotechnology companies, and CROs (Contract Research Organizations). It offers an opportunity for attendees to contribute their expertise and learn about the latest optimization, characterization, and PKPD strategies.

The meeting will be held in Frankfurt, Germany, providing a central location for attendees from various regions.